Christophe Parsy has dedicated his entire professional life to pharmaceutical R&D, in very international and fast paced environnements such as CRO, biotech and large pharma.
As Director of Medicinal Chemistry at Idenix Pharmaceuticals, he has developed a specific expertise in discovering drug candidates in anti-infective (HIV, HCV) and oncology. He notably contributed to the discovery of clinical candidates IDX320, Samatasvir et Uprifosbuvir to treat HCV. The advanced development of Uprifosbuvir has led to MSD acquiring Idenix Pharmaceuticals for USD 3.85 billion in August 2014.
Christophe Parsy is joint inventor of around twenty patents and joint author of numerous scientific publications. He holds a PhD. in organic chemistry from the University of Liverpool and an Executive MBA from Montpellier Business School.